Description of Research Expertise:
Dr. Dunbar is interested in atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of triglyceride-lowering drugs. He has worked with a variety of several novel triglyceride-lowering compounds, including niacin and novel niacin mimetics, fibrates and novel fibrates, novel fish oils, and a host of other emerging drugs: DGAT-1 inhibitor, MTP inhibitor, AngPTL3 inhibitor, ApoC3 inhibitor, a glitazar, and perhaps most uniquely, lipoprotein lipase gene replacement therapy. He also employs a variety of provoked outcomes in his research, such as oral fat tolerance testing with/without radiolabeled fat to trace chylomicrons, stable isotope lipoprotein kinetics, euglycemic-hyperinsulinemic clamp, FSIVGTT, indocyanine green to test hepatic function, other nutrient challenges, and a variety of modalities to measure niacin-associated skin toxicity. A common theme of these is the concept that perturbing a system reveals more as an outcome than the steady state. His research focuses on translating pre-clinical findings into humans, and indeed works exclusively on patient-oriented, clinical research.
Tuteja S, Wang L, Dunbar RL, Chen J, DerOhannessian S, Marcovina SM, Elam M, MD, Lader E, Rader DJ: Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2 (HCA2), and response to niacin therapy Pharmacogenetics and Genomics 27 (8): 285-293,2017.
Dewey FE*, Gusarova V*, Dunbar RL*, O’Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV , Bruse S, Dansky HM , Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH , Lee I-T, Liang K-W, Guo X, Rotter JI, Chen Y-D I on behalf of the TAICHI consortium, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjærg-Hansen A, van den Hoek AM: Genetic and Pharmacologic Inactivation of ANGPTL3 and Atherosclerotic Cardiovascular Disease N Engl J Med 377 (3): 211-221,2017.
Millar JS, Lassman ME, Thomas T, Ramakrishnan R, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Wagner JA, Holleran S, Obunike J, Liu Y, Aoujil S, Standiford T, Gutstein DE, Ginsberg HN, Rader DJ, Reyes-Soffer G: Effects of CETP Inhibition with Anacetrapib on Metabolism of VLDL TG and Plasma Apolipoproteins C-II, C-III, and E J Lipid Res 58 (6): 1214-1220,2017.
Ueda M*, Dunbar RL*, Wolska A, Sikora TU, del Rosario Escobar M, Seliktar N, deGoma E, DerOhannessian S, Morrell L, McIntyre AD, Burke F, Sviridov D, Amar M, Shamburek RD, Freeman L, Hegele RA, Remaley AT, Rader DJ: A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis. J Clin Endocrinol Metab 102 (5): 1454-1457,2017.
Ueda M, Burke FM, Walters L, Lalic D, Sikora, Greene H, DerOhannessian S, McIntyre A, deGoma E, Hegele RA, Rader DJ, Dunbar RL: Familial Chylomicron Syndrome: Importance of Discerning the Rare Among the Common J Clin Lip 11 (3): 2017.
Dunbar, RL: Signs, Symptoms and Awareness of FCS with Dr Richard Dunbar Rare Disease Report, accessioned from www.youtube.com/watch?v=M3SmD_Tse3o : 2017.
Goldberg AC, Dunbar RL, Hemphill L, Babirak SP, Wilson G, Wooten M, Moriarty PM: Retrospective Review of the Effect of Alirocumab on Apheresis J Clin Lip 11 (3): 2017.
Cuchel M, Raper AC, Pryma DA, Freifelder RH, Poria R, Cromley D, Li X, Dunbar RL, French B, Qu L, Farver W, Su C-C, Lund-Katz S, Baer A, Ruotolo G, Akerblad P, Ryan CS, Xiao L, Kirchgessner TG, Millar JS, Billheimer JT, Rader DJ: A Novel Approach to Measuring Macrophage-specific Reverse Cholesterol Transport in Vivo in Humans. J Lipid Res 58 (4): 752-762,2017.
Dunbar RL*, Goel H*, Tuteja S, Song W-L, Nathanson G, Babar Z, Lalic D, Gelfand JM, Rader DJ, Grove GL: Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics. J Lipid Res 58 (4): 783-797,2017.
Dunbar RL, Movva R, Bloedon LT, Duffy D, Norris RB, Navab M, Fogelman AM, Rader DJ: Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial
Clin Trans Science 10 : 2017.
View all publications